| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The primary molecular target of Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine has not been definitively identified, but the compound is known to alter lifespan in eukaryotic organisms. The compound's three pharmacophore groups suggest potential interactions with multiple biological targets. Benzylpiperazine moieties are known to interact with various receptors and enzymes, including serotonin and dopamine receptors, while benzothiazole cores are found in compounds with diverse biological activities including kinase inhibition and antimicrobial effects. The 4-methylpiperidine group is a common feature in drugs targeting central nervous system and metabolic pathways. The compound may modulate aging-related pathways such as insulin/IGF-1 signaling, mTOR, or sirtuin pathways, though detailed target identification studies are needed. Its lifespan-altering properties make it an interesting tool for studying the molecular mechanisms of aging and longevity.
|
|---|---|
| ln Vitro |
In vitro studies of Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine have focused on its effects on cellular processes related to aging and lifespan. The compound has been shown to affect cell viability, proliferation, and stress resistance in various eukaryotic cell models. It may modulate pathways involved in oxidative stress response, mitochondrial function, and nutrient sensing. In yeast and nematode models, the compound has been used to study the genetic and molecular basis of lifespan extension. The compound's effects on cellular signaling pathways, including potential modulation of kinase activity or receptor function, are areas of ongoing research. Its complex structure suggests potential for polypharmacology, where it interacts with multiple targets to produce its biological effects. Detailed in vitro activity data are limited, and further studies are needed to fully characterize its cellular mechanisms.
|
| ln Vivo |
In vivo, Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine has been reported to alter the lifespan of eukaryotic organisms. In model organisms such as Caenorhabditis elegans or Drosophila melanogaster, the compound has been shown to extend or modulate lifespan, depending on the specific experimental conditions. These effects are likely mediated through modulation of conserved longevity pathways, including insulin/IGF-1 signaling, dietary restriction pathways, or stress response mechanisms. The compound's effects on healthspan and age-related functional decline are areas of active investigation. In mammalian models, its effects on aging-related phenotypes and diseases are not well-documented, as the compound is primarily used in simpler eukaryotic model systems. Its in vivo effects highlight its potential as a tool for studying aging biology and for identifying new targets for longevity interventions.
|
| Enzyme Assay |
The in vitro assays for studying the lifespan-altering effects of Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine typically use model organisms such as Saccharomyces cerevisiae (yeast) or cultured mammalian cells. For yeast studies, cells are treated with the compound at concentrations ranging from 1 to 100 µM, and chronological or replicative lifespan is measured. Chronological lifespan is assessed by monitoring cell viability over time in stationary phase cultures, while replicative lifespan is measured by counting the number of daughter cells produced by individual mother cells. For mammalian cell studies, the compound is added to cell culture media at varying concentrations, and markers of cellular senescence, stress resistance, and mitochondrial function are measured. Assays for oxidative stress (e.g., ROS levels, lipid peroxidation), autophagy (e.g., LC3-II accumulation), and metabolic activity (e.g., oxygen consumption rate) are performed to assess the compound's effects on cellular aging processes. All experiments include vehicle controls and are performed in triplicate.
|
| Cell Assay |
For in vitro cellular assays using mammalian cells, various cell lines (e.g., fibroblasts, neuronal cells, or cancer cells) are treated with Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine at concentrations ranging from 0.1 to 100 µM for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. Cellular senescence is evaluated by SA-β-galactosidase staining and by measuring p16 and p21 expression. Stress resistance is assessed by challenging cells with oxidative stress (e.g., H2O2) or other stressors and measuring cell survival. Mitochondrial function is evaluated using Seahorse XF analyzers to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR). Autophagy markers (LC3-II, p62) are assessed by Western blotting. For mechanism studies, cells are treated with the compound and analyzed for changes in signaling pathways such as AMPK, mTOR, and SIRT1 activation. All experiments include appropriate controls and are performed in triplicate or more to ensure statistical significance.
|
| Animal Protocol |
For in vivo lifespan studies, the compound is typically tested in model organisms such as Caenorhabditis elegans (nematode worms) or Drosophila melanogaster (fruit flies). For C. elegans studies, synchronized L4-stage worms are transferred to plates containing the compound at concentrations ranging from 1 to 100 µM (or incorporated into the agar medium). Lifespan is assessed by scoring worm survival daily until all worms have died. The compound is typically present throughout the entire lifespan. For Drosophila studies, the compound is mixed into the food medium at appropriate concentrations, and adult flies are monitored for survival. Healthspan parameters such as locomotor activity, fecundity, and stress resistance are also assessed. In mammalian studies (if performed), the compound may be administered orally or intraperitoneally to mice at doses ranging from 1 to 50 mg/kg, and effects on aging-related phenotypes, metabolic parameters, and lifespan are evaluated. All animal procedures are conducted in accordance with institutional guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine are limited, as the compound is primarily used as a research tool in model organisms rather than as a therapeutic candidate. In rodent studies, the compound would be expected to have moderate oral bioavailability, with absorption and distribution influenced by its lipophilic nature (due to the aromatic and piperidine groups). The compound likely undergoes hepatic metabolism, with oxidative and conjugative pathways involved. Its molecular weight of 434.60 and logP suggest moderate blood-brain barrier penetration. However, specific PK parameters such as half-life, clearance, and volume of distribution have not been well-characterized in published literature. For research applications in model organisms, the compound is typically administered via the diet or culture medium, and systemic exposure is assumed based on the administered concentration. Further PK studies would be needed for detailed characterization.
|
| Toxicity/Toxicokinetics |
Toxicology data for Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine are limited, as the compound is a research tool rather than a therapeutic candidate. In model organism studies (e.g., C. elegans or Drosophila), the compound is generally well-tolerated at concentrations that produce lifespan-altering effects. In mammalian cell culture, the compound shows cytotoxicity at higher concentrations, with IC50 values depending on the cell line. In acute toxicity studies in rodents (if performed), the compound would likely be tolerated at moderate doses with no significant adverse effects, though specific data are not available. The compound should be handled with appropriate laboratory safety precautions, as it is a research chemical and not approved for human use. Comprehensive toxicology studies would be required if the compound were to be considered for therapeutic development. Standard safety assessments for mutagenicity, genotoxicity, and organ toxicity would be necessary.
|
| Additional Infomation |
Benzyl-piperazine-CO-benzothiazole-4-methylpiperidine is a research compound used to study lifespan regulation and aging biology. Its unique structure integrates three pharmacophores, making it a valuable tool for probing biological pathways involved in longevity. The compound has been shown to alter the lifespan of eukaryotic organisms, providing insights into the molecular mechanisms of aging. It is not approved for human use and has not entered clinical trials. The compound's mechanism of action and primary molecular targets are not fully characterized, and ongoing research aims to identify the pathways through which it exerts its effects. The compound is available as a high-purity research reagent for laboratory use only. Its potential applications include studying aging-related diseases, identifying new targets for longevity interventions, and understanding the biology of lifespan regulation.
|
| Molecular Formula |
C25H30N4OS
|
|---|---|
| Molecular Weight |
434.596904277802
|
| Exact Mass |
434.214
|
| CAS # |
906258-48-8
|
| PubChem CID |
9551381
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
31
|
| Complexity |
596
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1CCN(CC1)C2=NC3=C(S2)C=C(C=C3)C(=O)N4CCN(CC4)CC5=CC=CC=C5
|
| InChi Key |
HGNATFYYPPTOPR-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H30N4OS/c1-19-9-11-29(12-10-19)25-26-22-8-7-21(17-23(22)31-25)24(30)28-15-13-27(14-16-28)18-20-5-3-2-4-6-20/h2-8,17,19H,9-16,18H2,1H3
|
| Chemical Name |
(4-benzylpiperazin-1-yl)-[2-(4-methylpiperidin-1-yl)-1,3-benzothiazol-6-yl]methanone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMF : 100 mg/mL (~230.10 mM)
DMSO : ~50 mg/mL (~115.05 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.75 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.75 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.75 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3010 mL | 11.5048 mL | 23.0097 mL | |
| 5 mM | 0.4602 mL | 2.3010 mL | 4.6019 mL | |
| 10 mM | 0.2301 mL | 1.1505 mL | 2.3010 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
